向蛋白氨酸酸酶非受体6型 (PTPN6) 作为急性髓性白血病的治疗策略

Xiaoou Wang1, Zhenggang Li2, Jing Shen3

  • 1Department of Hematology, The Fourth Affiliated Hospital of China Medical University, Shenyang, 110032, People's Republic of China.

Cell biology and toxicology
|December 20, 2024
PubMed
概括

向蛋白氨酸酸酶非受体6型 (PTPN6) 显示出急性髓性白血病 (AML) 治疗的前景. 抑制PTPN6可以减少AML细胞的生长,促进分化,并提高化疗的有效性.